Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin

被引:250
作者
Bayry, J
Lacroix-Desmazes, S
Carbonneil, C
Misra, N
Donkova, V
Pashov, A
Chevailler, A
Mouthon, L
Weill, B
Bruneval, P
Kazatchkine, MD
Kaveri, SV
机构
[1] Inst Biomed Cordeliers, INSERM U430, F-75006 Paris, France
[2] Univ Paris 06, Inst Cordeliers, Paris, France
[3] Hop Cochin, Lab Immunol Biol, F-75674 Paris, France
[4] Hop Avicenne, Serv Med Interne, Paris, France
[5] Univ Angers, Lab Immunol & Immunopathol, Angers, France
关键词
D O I
10.1182/blood-2002-05-1447
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Normal immunoglobulin G for therapeutic use (intravenous immunoglobulin [IVIg]) is used in an increasing number of immune-mediated conditions, including acute and chronic/relapsing autoimmune diseases, transplantation, and systemic inflammatory disorders. Several mutually nonexclusive mechanisms of action account for the immunoregulatory effects of IVIg. Although IVIg inhibits T-cell proliferation and T-cell cytokine production, it is unclear whether these effects are directly dependent on the effects of IVIg on T cells or they are dependent through the inhibition of antigen-presenting cell activity. Here, we examined the effects of IVIg on differentiation, maturation, and function of dendritic cells (DCs). We show that IVIg inhibits the differentiation and maturation of DCs in vitro and abrogates the capacity of mature DC to secrete interleukin-12 (IL-12) on activation while enhancing IL-10 production. IVIg-induced down-regulation of costimulatory molecules associated with modulation of cytokine secretion resulted in the inhibition of autoreactive and alloreactive T-cell activation and proliferation. Modulation of DC maturation and function by IVIg is of potential relevance to its immunomodulatory effects in controlling specific immune responses in autoimmune diseases, transplantation, and other immune-mediated conditions. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:758 / 765
页数:8
相关论文
共 63 条
  • [1] Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO
  • [2] 2-4
  • [3] Fcγ receptors and cross-presentation in dendritic cells
    Amigorena, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (01) : F1 - F3
  • [4] POOLED HUMAN-IGG MODULATES CYTOKINE PRODUCTION IN LYMPHOCYTES AND MONOCYTES
    ANDERSSON, U
    BJORK, L
    SKANSENSAPHIR, U
    ANDERSSON, J
    [J]. IMMUNOLOGICAL REVIEWS, 1994, 139 : 21 - 42
  • [5] Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases
    Ballow, M
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (02) : 151 - 157
  • [6] Immunobiology of dendritic cells
    Banchereau, J
    Briere, F
    Caux, C
    Davoust, J
    Lebecque, S
    Liu, YT
    Pulendran, B
    Palucka, K
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 : 767 - +
  • [7] Dendritic cells and the control of immunity
    Banchereau, J
    Steinman, RM
    [J]. NATURE, 1998, 392 (6673) : 245 - 252
  • [8] THERAPY FOR PATIENTS WITH RECURRENT INFECTIONS AND LOW SERUM IGG3 LEVELS
    BARLAN, IB
    GEHA, RS
    SCHNEIDER, LC
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 92 (02) : 353 - 355
  • [9] Caccavelli L, 2001, EUR J IMMUNOL, V31, P2781, DOI 10.1002/1521-4141(200109)31:9<2781::AID-IMMU2781>3.0.CO
  • [10] 2-Z